Clinical trials: sponsored by H. Lundbeck A/S
Alcohol Dependence
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.
- Trial name
- SENSE (NCT00811941)
- Testing
- Nalmefene
- Where
- 60 sites in Czechia, Estonia and 8 more
- Volunteers
- 665 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
- Trial name
- ESENSE2 (NCT00812461)
- Testing
- Nalmefene
- Where
- 57 sites in Belgium, Czechia and 5 more
- Volunteers
- 678 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
- Trial name
- ESENSE1 (NCT00811720)
- Testing
- Nalmefene
- Where
- 39 sites in Austria, Finland and 2 more
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Healthy
Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women
The rationale for this pharmacokinetic (PK) study is to determine the PK parameters for Lu AA21004 (Vortioxetine) in the Chinese population.
- Trial name
- NCT01676571
- Testing
- Lu AA21004
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive…
- Trial name
- NCT00807248
- Testing
- Escitalopram 20 mg, Gaboxadol 5 mg, Gaboxadol 10 mg
- Where
- 22 sites in Austria, Russia
- Volunteers
- 490 people
- Sponsor
- H. Lundbeck A/S
Healthy
Bioequivalence Study Comparing Two Formulations of Escitalopram
This is a bioequivalence study, which is a regulatory requirement to ensure comparable in vivo performance, i.e. similarities in terms of safety and efficacy, after administration of two different dosage forms of escitalopram.
- Trial name
- NCT01395433
- Testing
- Escitalopram
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons.
- Trial name
- NCT00862940
- Testing
- Memantine
- Volunteers
- 277 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
The purpose of this study is to fulfil regulatory requirements for registration of a new chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease (PD) in Europe and the US.
- Trial name
- NCT01652313
- Testing
- Rasagiline
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease
The purpose of this study is to accept or reject the hypothesis that Lu AE58054 improves cognition and functional outcomes in patients with moderate Alzheimer's Disease, already in treatment with donepezil.
- Trial name
- NCT01019421
- Testing
- Lu AE58054
- Where
- 51 sites in Australia, Canada and 5 more
- Volunteers
- 278 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal…
- Trial name
- SCoP (NCT00856583)
- Testing
- Sertindole, Risperidone
- Volunteers
- 9,809 people
- Sponsor
- H. Lundbeck A/S
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Generalized Anxiety Disorder
Escitalopram in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the…
- Trial name
- NCT00902564
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Acute Ischemic Stroke
Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) dosed once daily for 5 days is a safe treatment for patients who have suffered an acute ischemic stroke.
- Trial name
- NCT00870844
- Testing
- Lu AA24493 (CEPO)
- Where
- 5 sites in Finland, France and 3 more
- Volunteers
- 24 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.
- Trial name
- NCT00766870
- Testing
- Lu AA34893, Venlafaxine extended release
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00704509
- Testing
- Bifeprunox, Quetiapine
- Where
- 45 sites in India, Indonesia and 5 more
- Volunteers
- 346 people
- Sponsor
- H. Lundbeck A/S
Depression in Patients With Bipolar Disorder
Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00622245
- Testing
- Lu AA34893, Quetiapine fumarate
- Where
- 50 sites in Australia, Austria and 16 more
- Volunteers
- 166 people
- Sponsor
- H. Lundbeck A/S
Acute Ischemic Stroke
Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.
- Trial name
- NCT00756249
- Testing
- Lu AA24493 (CEPO)
- Where
- 5 sites in Finland, France and 3 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00658645
- Testing
- Bifeprunox, Quetiapine
- Where
- 38 sites in Bulgaria, China and 6 more
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209950
- Testing
- Gaboxadol
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- H. Lundbeck A/S